Second generation prognostic genomic tests in early breast cancer: EndoPredict® y Prosigna™.
Martínez-Férez IM, Isabel-Gómez, Beltrán-Calvo C.
Record ID 32018000420
Spanish
Original Title:
Plataformas genómicas de segunda generación para el pronóstico del cáncer de mama: EndoPredict® y Prosigna™. Revisión sistemática.
Authors' objectives:
To assess the efficacy (analytical and clinical validation) and clinical utility of Prosigna ™ and EndoPredict® as prognostic tests in early breast cancer.
Authors' results and conclusions:
• EndoPredict® and Prosigna ™ have showed analytical validity, measured as precision and reproducibility of assay.
• EndoPredict® EP and EPclin scores are independent prognosis factors. These scores provided additional prognostic information on distant recurrence to the clinicopathological factors in pre and postmenopausal women with ER-positive, HER2-negative, node-negative early breast cancer at 10 years. The assay showed a good discrimination capacity between the low and high distant recurrence groups.
• Prosigna ™ ROR score is an independent prognosis factor and adds prognostic information on distant recurrence to the clinicopathological factors in postmenopausal women with HR-positive, node-negative, node-positive early breast cancer at 10 years. The assay showed a good discrimination capacity between the three distant recurrence groups: low, intermediate and high.
• EndoPredict® seemed to have an impact on therapeutic decision making, reducing chemotherapy.
• The clinical utility of both assays, and so their potential benefits in breast cancer remain unclear.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
https://www.aetsa.org/publicacion/plataformas-genomicas-de-segunda-generacion-para-el-pronostico-del-cancer-de-mama-endopredict-y-prosigna-revision-sistematica/
English language abstract:
An English language summary is available
Publication Type:
Mini HTA
Country:
Spain
MeSH Terms
- Breast Neoplasms
- Gene Expression Profiling
- Genomics
- Female
- Prognosis
Keywords
- Cáncer de mama
- Perfilación de la expresión génica
- Genómica
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Health Technology Assessment Area (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.